MedImmune CEO talks about AZ buyout

MedImmune's chief executive talked publicly for the first time about AstraZeneca's April takeover of his company--and his assessment of his new corporate parent is, not surprisingly, positive. David M. Mott did get to keep his job, and MedImmune is adding to its staff of 3,000, rather than slicing away at jobs as the rest of AstraZeneca is. Plus, Mott expects R&D spending to ramp up significantly, to $1 billion by 2010 from $400 million last year. Big Pharma is fun, he essentially said. It probably helps that he made a cool $145 million off the deal himself.

- check out the report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.